{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:11Z","timestamp":1791417611825,"version":"4.3.3"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jem-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Emergency Medicine"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jemermed.2018.07.005","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T10:10:12Z","timestamp":1534414212000},"page":"489-502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians"],"prefix":"10.1016","volume":"55","author":[{"given":"Adam T.","family":"Hryniewicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Shatsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Coyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jemermed.2018.07.005_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2018.07.005_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jemermed.2018.07.005_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrclinonc.2017.15","article-title":"Approvals in 2016: the march of the checkpoint inhibitors","volume":"14","author":"Blumenthal","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jemermed.2018.07.005_bib4","doi-asserted-by":"crossref","first-page":"T331","DOI":"10.1530\/ERC-17-0358","article-title":"Endocrine side effects of cancer immunotherapy","volume":"24","author":"Cukier","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.jemermed.2018.07.005_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jemermed.2018.07.005_bib6","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jemermed.2018.07.005_bib7","first-page":"185","article-title":"The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge","volume":"41","author":"Alexander","year":"2016","journal-title":"P T"},{"key":"10.1016\/j.jemermed.2018.07.005_bib8","series-title":"Yervoy\u00ae (ipilumumab) [package insert]","author":"Bristol-Myers Squibb Company","year":"2017"},{"key":"10.1016\/j.jemermed.2018.07.005_bib9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jemermed.2018.07.005_bib10","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/infdis\/jix191","article-title":"Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy","volume":"215","author":"Gay","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jemermed.2018.07.005_bib11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jemermed.2018.07.005_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jemermed.2018.07.005_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.jemermed.2018.07.005_bib14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jemermed.2018.07.005_bib15","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jemermed.2018.07.005_bib16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.revmed.2017.01.004","article-title":"Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): an emerging challenge","volume":"38","author":"Kostine","year":"2017","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.jemermed.2018.07.005_bib17","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1634\/theoncologist.2017-0133","article-title":"Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors","volume":"22","author":"Judd","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jemermed.2018.07.005_bib18","volume":"4.03","year":"2010"},{"key":"10.1016\/j.jemermed.2018.07.005_bib19","article-title":"Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience","author":"Fujii","year":"2017","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jemermed.2018.07.005_bib20","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jemermed.2018.07.005_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.jemermed.2018.07.005_bib22","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jemermed.2018.07.005_bib23","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2018.07.005_bib24","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1002\/ijc.31012","article-title":"The clinical value of combination of immune checkpoint inhibitors in cancer patients: a meta-analysis of efficacy and safety","volume":"141","author":"Wu","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jemermed.2018.07.005_bib25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jemermed.2018.07.005_bib26","doi-asserted-by":"crossref","first-page":"e0160485","DOI":"10.1371\/journal.pone.0160485","article-title":"PD-1 antibody monotherapy for malignant melanoma: a systematic review and meta-analysis","volume":"11","author":"Lin","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jemermed.2018.07.005_bib27","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2018.07.005_bib28","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.clon.2016.11.007","article-title":"Treatment-related death in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"29","author":"Abdel-Rahman","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.jemermed.2018.07.005_bib29","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jemermed.2018.07.005_bib30","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1158\/2326-6066.CIR-14-0217","article-title":"Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center","volume":"3","author":"Johnson","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jemermed.2018.07.005_bib31","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jemermed.2018.07.005_bib32","doi-asserted-by":"crossref","first-page":"W468","DOI":"10.2214\/AJR.12.9751","article-title":"Ipilimumab-associated colitis: CT findings","volume":"200","author":"Kim","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jemermed.2018.07.005_bib33","series-title":"KEYTRUDA\u00ae (pembrolizumab) (package insert)","author":"Merck Sharpe and Dohme Corporation","year":"2015"},{"key":"10.1016\/j.jemermed.2018.07.005_bib34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jemermed.2018.07.005_bib35","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2018.07.005_bib36","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2018.07.005_bib37","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jemermed.2018.07.005_bib38","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","article-title":"The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis","volume":"69","author":"Minkis","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jemermed.2018.07.005_bib39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/CJI.0000000000000076","article-title":"Delayed dermatologic hypersensitivity reaction secondary to ipilimumab","volume":"38","author":"Ludlow","year":"2015","journal-title":"J Immunother"},{"key":"10.1016\/j.jemermed.2018.07.005_bib40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jemermed.2018.07.005_bib41","doi-asserted-by":"crossref","first-page":"44173","DOI":"10.1038\/srep44173","article-title":"PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jemermed.2018.07.005_bib42","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jemermed.2018.07.005_bib43","doi-asserted-by":"crossref","DOI":"10.14694\/EdBook_AM.2013.33.e280","article-title":"Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer","author":"Chow","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jemermed.2018.07.005_bib44","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jemermed.2018.07.005_bib45","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jemermed.2018.07.005_bib46","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.jemermed.2018.07.005_bib47","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2174\/0929867324666170407125017","article-title":"Immune checkpoint inhibitors and cardiac toxicity: an emerging issue","volume":"25","author":"Varricchi","year":"2018","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jemermed.2018.07.005_bib48","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jemermed.2018.07.005_bib49","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.jemermed.2018.07.005_bib50","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ejca.2013.10.016","article-title":"Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review","volume":"50","author":"Huillard","year":"2014","journal-title":"Eur J Cancer"}],"container-title":["The Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467918306607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467918306607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:41:12Z","timestamp":1760028072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0736467918306607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0736467918306607"],"URL":"https:\/\/doi.org\/10.1016\/j.jemermed.2018.07.005","relation":{},"ISSN":["0736-4679"],"issn-type":[{"value":"0736-4679","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians","name":"articletitle","label":"Article Title"},{"value":"The Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jemermed.2018.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}